Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Disease–Associated Pulmonary Hypertension

BACKGROUND: Endostatin, an angiogenic inhibitor, is associated with worse pulmonary arterial hypertension (PAH) outcomes in adults and poor lung growth in children. This study sought to assess whether endostatin is associated with disease severity and outcomes in pediatric PAH. METHODS AND RESULTS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Daly, Caroline M., Griffiths, Megan, Simpson, Catherine E., Yang, Jun, Damico, Rachel L., Vaidya, R. Dhananjay, Williams, Monica, Brandal, Stephanie, Jone, Pei‐Ni, Polsen, Cassandra, Ivy, D. Dunbar, Austin, Eric D., Nichols, William C., Pauciulo, Michael W., Lutz, Katie, Nies, Melanie K., Rosenzweig, Erika B., Hirsch, Russel, Yung, Delphine, Everett, Allen D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751905/
https://www.ncbi.nlm.nih.gov/pubmed/34622662
http://dx.doi.org/10.1161/JAHA.120.021409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751905/
https://www.ncbi.nlm.nih.gov/pubmed/34622662
http://dx.doi.org/10.1161/JAHA.120.021409

Ejemplares similares